Many studies, including our own, had focused on the features and the behavior of cancer cells after uPAR cleavage or downregulation, both in vitro and in vivo, using anti-uPAR oligodeoxynucleotide (ODN) (13, 14) and miRNA (15), exploiting uPAR inactivation specific cleavage systems such as MMP-12 (16), or inhibiting its interaction with the complex “uPAR interactome” by a specific uncoupler peptide (17). The gene discussed is PLAUR; the disease is cancer.